This class of antagonists induces a degradation of the ERα receptor; their potential to block endocrine- and non-endocrine-dependent signaling has been recognized to offer a therapeutic approach in early-stage disease and improves outcomes for those with advanced ER+-resistant breast cancer [4, 5]. The gene discussed is ESR1; the disease is breast carcinoma.